APO RESEARCH · REPORT
PD-L1 Biomarker Testing
PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.
Product & engineering
Understand the product.
PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.
Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart).
PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti–PD-1/PD-L1 therapies.
PDL1 testing is used to find out if you have a cancer that may benefit from immunotherapy.
Selected research
Industry Research
PD-L1 Biomarker Testing Industry Research Report 2026
Market perspective
PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.
Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart).
PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti–PD-1/PD-L1 therapies.
Read the full market overview
PDL1 testing is used to find out if you have a cancer that may benefit from immunotherapy.
The classification of PD-L1 Biomarker Testing includes PD-L1 (22C3), PD-L1 (28-8), PD-L1 (SP142), PD-L1 (SP263) and Other, and the revenue proportion of PD-L1 (22C3) in 2019 is about 21.68%.
PD-L1 Biomarker Testing is widely used in Hospital and Diagnostic Laboratories. The most proportion of PD-L1 Biomarker Testing is Hospital, and the proportion in 2019 is about 52.7%.
North Americas is the largest consumption place, with a consumption market share nearly 55.63% in 2019. Following North Americas, Europe is the second largest consumption place with the consumption market share of 26.7%.
Report Scope
This report quantifies the global PD-L1 Biomarker Testing market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to PD-L1 Biomarker Testing.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
PD-L1 Biomarker Testing Market by Company
Agilent Technologies
Roche
Merck
Bristol-Myers Squibb
AstraZeneca
Ono Pharmaceutical
Regeneron
Innovent
Hengrui Medicine
Junshi Biosciences
PD-L1 Biomarker Testing Segment by Type
PD-L1 (22C3)
PD-L1(28-8)
PD-L1 (SP142)
PD-L1 (SP263)
Other
PD-L1 Biomarker Testing Segment by Application
Hospital
Diagnostic Center
Others
PD-L1 Biomarker Testing Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PD-L1 Biomarker Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of PD-L1 Biomarker Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PD-L1 Biomarker Testing.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of PD-L1 Biomarker Testing companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- PD-L1 (22C3)
- PD-L1(28-8)
- PD-L1 (SP142)
- PD-L1 (SP263)
- Other
Applications
- Hospital
- Diagnostic Center
- Others
Companies covered
- Agilent Technologies
- Roche
- Merck
- Bristol-Myers Squibb
- AstraZeneca
- Ono Pharmaceutical
- Regeneron
- Innovent
- Hengrui Medicine
- Junshi Biosciences
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 PD-L1 Biomarker Testing by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 PD-L1 (22C3)
- 2.2.3 PD-L1(28-8)
- 2.2.4 PD-L1 (SP142)
- 2.2.5 PD-L1 (SP263)
- 2.2.6 Other
- 2.3 PD-L1 Biomarker Testing by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Diagnostic Center
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 PD-L1 Biomarker Testing Breakdown Data by Type
- 3.1 Global PD-L1 Biomarker Testing Historic Market Size by Type (2021-2026)
- 3.2 Global PD-L1 Biomarker Testing Forecasted Market Size by Type (2027-2032)
4 PD-L1 Biomarker Testing Breakdown Data by Application
- 4.1 Global PD-L1 Biomarker Testing Historic Market Size by Application (2021-2026)
- 4.2 Global PD-L1 Biomarker Testing Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global PD-L1 Biomarker Testing Market Perspective (2021-2032)
- 5.2 Global PD-L1 Biomarker Testing Growth Trends by Region
- 5.2.1 Global PD-L1 Biomarker Testing Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 PD-L1 Biomarker Testing Historic Market Size by Region (2021-2026)
- 5.2.3 PD-L1 Biomarker Testing Forecasted Market Size by Region (2027-2032)
- 5.3 PD-L1 Biomarker Testing Market Dynamics
- 5.3.1 PD-L1 Biomarker Testing Industry Trends
- 5.3.2 PD-L1 Biomarker Testing Market Drivers
- 5.3.3 PD-L1 Biomarker Testing Market Challenges
- 5.3.4 PD-L1 Biomarker Testing Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top PD-L1 Biomarker Testing Players by Revenue
- 6.1.1 Global Top PD-L1 Biomarker Testing Players by Revenue (2021-2026)
- 6.1.2 Global PD-L1 Biomarker Testing Revenue Market Share by Players (2021-2026)
- 6.2 Global PD-L1 Biomarker Testing Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of PD-L1 Biomarker Testing Head Office and Area Served
- 6.4 Global PD-L1 Biomarker Testing Players, Product Type & Application
- 6.5 Global PD-L1 Biomarker Testing Manufacturers Established Date
- 6.6 Global PD-L1 Biomarker Testing Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America PD-L1 Biomarker Testing Market Size (2021-2032)
- 7.2 North America PD-L1 Biomarker Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America PD-L1 Biomarker Testing Market Size by Country (2021-2026)
- 7.4 North America PD-L1 Biomarker Testing Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe PD-L1 Biomarker Testing Market Size (2021-2032)
- 8.2 Europe PD-L1 Biomarker Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe PD-L1 Biomarker Testing Market Size by Country (2021-2026)
- 8.4 Europe PD-L1 Biomarker Testing Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific PD-L1 Biomarker Testing Market Size (2021-2032)
- 9.2 Asia-Pacific PD-L1 Biomarker Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific PD-L1 Biomarker Testing Market Size by Country (2021-2026)
- 9.4 Asia-Pacific PD-L1 Biomarker Testing Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America PD-L1 Biomarker Testing Market Size (2021-2032)
- 10.2 South America PD-L1 Biomarker Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America PD-L1 Biomarker Testing Market Size by Country (2021-2026)
- 10.4 South America PD-L1 Biomarker Testing Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa PD-L1 Biomarker Testing Market Size (2021-2032)
- 11.2 Middle East & Africa PD-L1 Biomarker Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa PD-L1 Biomarker Testing Market Size by Country (2021-2026)
- 11.4 Middle East & Africa PD-L1 Biomarker Testing Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Agilent Technologies
- 12.1.1 Agilent Technologies Company Information
- 12.1.2 Agilent Technologies Business Overview
- 12.1.3 Agilent Technologies Revenue in PD-L1 Biomarker Testing Business (2021-2026)
- 12.1.4 Agilent Technologies PD-L1 Biomarker Testing Product Portfolio
- 12.1.5 Agilent Technologies Recent Developments
- 12.2 Roche
- 12.2.1 Roche Company Information
- 12.2.2 Roche Business Overview
- 12.2.3 Roche Revenue in PD-L1 Biomarker Testing Business (2021-2026)
- 12.2.4 Roche PD-L1 Biomarker Testing Product Portfolio
- 12.2.5 Roche Recent Developments
- 12.3 Merck
- 12.3.1 Merck Company Information
- 12.3.2 Merck Business Overview
- 12.3.3 Merck Revenue in PD-L1 Biomarker Testing Business (2021-2026)
- 12.3.4 Merck PD-L1 Biomarker Testing Product Portfolio
- 12.3.5 Merck Recent Developments
- 12.4 Bristol-Myers Squibb
- 12.4.1 Bristol-Myers Squibb Company Information
- 12.4.2 Bristol-Myers Squibb Business Overview
- 12.4.3 Bristol-Myers Squibb Revenue in PD-L1 Biomarker Testing Business (2021-2026)
- 12.4.4 Bristol-Myers Squibb PD-L1 Biomarker Testing Product Portfolio
- 12.4.5 Bristol-Myers Squibb Recent Developments
- 12.5 AstraZeneca
- 12.5.1 AstraZeneca Company Information
- 12.5.2 AstraZeneca Business Overview
- 12.5.3 AstraZeneca Revenue in PD-L1 Biomarker Testing Business (2021-2026)
- 12.5.4 AstraZeneca PD-L1 Biomarker Testing Product Portfolio
- 12.5.5 AstraZeneca Recent Developments
- 12.6 Ono Pharmaceutical
- 12.6.1 Ono Pharmaceutical Company Information
- 12.6.2 Ono Pharmaceutical Business Overview
- 12.6.3 Ono Pharmaceutical Revenue in PD-L1 Biomarker Testing Business (2021-2026)
- 12.6.4 Ono Pharmaceutical PD-L1 Biomarker Testing Product Portfolio
- 12.6.5 Ono Pharmaceutical Recent Developments
- 12.7 Regeneron
- 12.7.1 Regeneron Company Information
- 12.7.2 Regeneron Business Overview
- 12.7.3 Regeneron Revenue in PD-L1 Biomarker Testing Business (2021-2026)
- 12.7.4 Regeneron PD-L1 Biomarker Testing Product Portfolio
- 12.7.5 Regeneron Recent Developments
- 12.8 Innovent
- 12.8.1 Innovent Company Information
- 12.8.2 Innovent Business Overview
- 12.8.3 Innovent Revenue in PD-L1 Biomarker Testing Business (2021-2026)
- 12.8.4 Innovent PD-L1 Biomarker Testing Product Portfolio
- 12.8.5 Innovent Recent Developments
- 12.9 Hengrui Medicine
- 12.9.1 Hengrui Medicine Company Information
- 12.9.2 Hengrui Medicine Business Overview
- 12.9.3 Hengrui Medicine Revenue in PD-L1 Biomarker Testing Business (2021-2026)
- 12.9.4 Hengrui Medicine PD-L1 Biomarker Testing Product Portfolio
- 12.9.5 Hengrui Medicine Recent Developments
- 12.10 Junshi Biosciences
- 12.10.1 Junshi Biosciences Company Information
- 12.10.2 Junshi Biosciences Business Overview
- 12.10.3 Junshi Biosciences Revenue in PD-L1 Biomarker Testing Business (2021-2026)
- 12.10.4 Junshi Biosciences PD-L1 Biomarker Testing Product Portfolio
- 12.10.5 Junshi Biosciences Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst